Silence Therapeutics plc 5.3% stake
- Tetragon Financial Management LP holds 5.3% of shares
- 9,878,565 shares beneficially owned
- Includes 1,500,000 Shares issuable upon exercise of call options
Tetragon Financial Management LP, filed by
SLN
Silence Therapeutics plc SEC filings
Every EDGAR filing for Silence Therapeutics plc (SLN), newest first, with AI summaries and stories.
- Ticker
- SLN
- CIK
- 1479615
- Latest filing
- 5d
Next: earnings expected ~Nov 9 · 10-Q expected ~Nov 9 (deadline Nov 16)
Filings
SCHEDULE 13G/ASilence Therapeutics plcSLNCFLIVE SCHEDULE 13GSilence Therapeutics plcSLNCFLIVE Silence Therapeutics plc
- Tetragon Financial Management LP filed Schedule 13G on 2026-10-13.
- Owns 9,708,153 shares (5.2% of class).
- Includes 1,500,000 Shares underlying 500,000 ADSs.
Tetragon Financial Management LP, filed by
SCHEDULE 13D/ASilence Therapeutics plcSLNCFLIVE Ownership stake disclosure by Richard Ian Griffiths (amended)
Richard Ian Griffiths, filed by
SCHEDULE 13G/ASilence Therapeutics plcSLNCFLIVE Ownership stake disclosure by Invus Global Management, LLC (amended)
Invus Global Management, LLC, filed by
4Silence Therapeutics plcSLNCFLIVE Richard Ian Griffiths, insider filing for SLNCF
Richard Ian Griffiths, reporting
8-KSilence Therapeutics plcSLNCFLIVE 424B5Silence Therapeutics plcSLNCFLIVE S-3MEFSilence Therapeutics plcSLNCFLIVE 424B5Silence Therapeutics plcSLNCFLIVE 8-KSilence Therapeutics plcSLNCFLIVE 10-QSilence Therapeutics plcSLNCFLIVE 8-KSilence Therapeutics plcSLNCFLIVE 8-K/ASilence Therapeutics plcSLNCFLIVE SCHEDULE 13D/ASilence Therapeutics plcSLNCFLIVE Ownership stake disclosure by Richard Ian Griffiths (amended)
Richard Ian Griffiths, filed by
4Silence Therapeutics plcSLNCFLIVE Richard Ian Griffiths, insider filing for SLNCF
Richard Ian Griffiths, reporting
8-KSilence Therapeutics plcSLNCFLIVE 8-KSilence Therapeutics plcSLNCFLIVE 8-KSilence Therapeutics plcSLNCFLIVE EFFECTSilence Therapeutics plcSLNCFLIVE 424B5Silence Therapeutics plcSLNCFLIVE 8-KSilence Therapeutics plcSLNCFLIVE S-3Silence Therapeutics plcSLNCFLIVE 10-QSilence Therapeutics plcSLNCFLIVE 8-KSilence Therapeutics plcSLNCFLIVE ARSSilence Therapeutics plcSLNCFLIVE DEF 14ASilence Therapeutics plcSLNCFLIVE S-8Silence Therapeutics plcSLNCFLIVE 10-KSilence Therapeutics plcSLNCFLIVE 8-KSilence Therapeutics plcSLNCFLIVE 4Silence Therapeutics plcSLNCFLIVE Richard Ian Griffiths, insider filing for SLNCF
Richard Ian Griffiths, reporting
SCHEDULE 13G/ASilence Therapeutics plcSLNCFLIVE Ownership stake disclosure by Lombard Odier Asset Management (USA) Corp (amended)
Lombard Odier Asset Management (USA) Corp, filed by
4Silence Therapeutics plcSLNCFLIVE 5 insider filings
James Ede-Golightly, insider filing for SLNCF
Show all 5
- 4Insider filing for SLNCF
- 4Insider filing for SLNCF
- 4Insider filing for SLNCF
- 4Insider filing for SLNCF
- 4Insider filing for SLNCF
James Ede-Golightly, reporting
4Silence Therapeutics plcSLNCFLIVE 3 insider filings
Iain Ross, insider filing for SLNCF
Show all 3
- 4Insider filing for SLNCF
- 4Insider filing for SLNCF
- 3New insider at SLNCF
Iain Ross, reporting
8-K/ASilence Therapeutics plcSLNCFLIVE 8-KSilence Therapeutics plcSLNCFLIVE 8-KSilence Therapeutics plcSLNCFLIVE 10-QSilence Therapeutics plcSLNCFLIVE 8-KSilence Therapeutics plcSLNCFLIVE